NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

February 26, 2027

Study Completion Date

February 26, 2027

Conditions

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney CancerRenal CancerRenal Cell CarcinomaRenal Cell Cancer MetastaticRenal Cell Carcinoma RecurrentRenal Cell Cancer, RecurrentKidney

Interventions

DRUG

Belzutifan

Belzutifan tablets administered orally.

DRUG

Cabozantinib

Cabozantinib tablets administered orally.

Trial Locations (10)

33136

Sylvester Comprehensive Cancer Center ( Site 0023), Miami

37203

Tennessee Oncology, PLLC ( Site 0001), Nashville

37404

Tennessee Oncology, PLLC ( Site 0024), Chattanooga

48201

Karmanos Cancer Institute ( Site 0033), Detroit

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 0010), Dallas

90033

USC Norris Comprehensive Cancer Center ( Site 0060), Los Angeles

90048

Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003), Los Angeles

98104

Swedish Cancer Institute ( Site 0018), Seattle

98109

Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0035), Seattle

02215

Dana Farber Cancer Center ( Site 0006), Boston

All Listed Sponsors

lead

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY